$5.55M Teva, Granules and Heritage metformin class action settlement

Teva Pharmaceuticals, Granules USA and Heritage Pharmaceuticals agreed to pay a combined $5.55 million class action settlement to resolve claims their metformin products were contaminated with cancer-causing N-nitrosodimethylamine (NDMA).

The metformin class action settlement benefits consumers who paid for Teva, Granules or Heritage metformin products between July 20, 2015, and June 2, 2020.

According to the class action lawsuit, Teva, Granules and Heritage manufactured metformin-containing drugs that were contaminated with NDMA, a probable human carcinogen. The products allegedly failed to meet the U.S. Food and Drug Administration standards for metformin.

Metformin is a diabetes medication. Teva, Granules and Heritage manufactured generic versions of Glucophage and Glucophage XR, brand-name metformin products.

The companies have not admitted any wrongdoing but agreed to a $5.55 million class action settlement to resolve the metformin-containing drugs class action lawsuit. Teva agreed to a $3 million settlement and Granules and Heritage have agreed to a $2.55 million settlement.

Under the terms of the metformin settlement, class members can receive a cash payment based on how much they paid for metformin-containing drugs, with amounts varying depending on the number of claims filed and eligible purchase costs.

The deadline for exclusion and objection is July 10, 2026.

The final approval hearing for the Teva, Granules and Heritage metformin settlement is scheduled for Aug. 12, 2026.

To receive settlement benefits, class members must submit a valid claim form by July 10, 2026.

Who’s Eligible

The class action settlement benefits individuals and entities who paid any amount of money for a metformin-containing drug (intended for personal or household use) that was manufactured, distributed or sold by Teva, Granules or Heritage from July 20, 2015, through June 2, 2020.

Potential Award

Varies

Proof of Purchase

Documentation of purchases, such as pharmacy receipts, invoices or other records.

Claim Form

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

07/10/2026

Case Name

In re: Metformin Marketing and Sales Practices Litigation, Case No. 2:20-cv-2324, in the U.S. District Court for the District of New Jersey

Final Hearing

08/12/2026

Settlement Website

InReMetforminSettlement.com

Claims Administrator

In re Metformin Marketing and Sales Practices Litigation
c/o A.B. Data Ltd.
P.O. Box 173012
Milwaukee, WI 53217
[email protected]
866-302-6835

Class Counsel

James E. Cecchi
Donald Ecklund
CARELLA, BYRNE, CECCHI, BRODY & AGNELLO PC

Ruben Honik
HONIK LLC

Defense Counsel

Asher A. Block
LEWIS BRISBOIS BISGAARD & SMITH LLP

Liza M. Walsh
Christine I. Gannon
WALSH PIZZI O’REILLY FALANGA LLP